机构名称：
¥ 1.0
The board of directors (the “ Board ”) of Sino Biopharmaceutical Limited (the “ Company ”, together with its subsidiaries, the “ Group ”) announces that three research results of two innovative drugs developed by the Group, “TQC3721 (PDE3/4 inhibitor)” and “TQC2731 (TSLP monoclonal antibody)”, will be presented at the 2024 annual meeting of欧洲呼吸学会（ERS 2024）将于9月7日至11日举行。
自愿公告
主要关键词
相关文件推荐
